Los Angeles Capital Management & Equity Research Inc. Purchases Shares of 2,180 Sarepta Therapeutics Inc (SRPT)

Los Angeles Capital Management & Equity Research Inc. purchased a new stake in Sarepta Therapeutics Inc (NASDAQ:SRPT) in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 2,180 shares of the biotechnology company’s stock, valued at approximately $260,000.

Other institutional investors also recently added to or reduced their stakes in the company. Northern Trust Corp boosted its holdings in shares of Sarepta Therapeutics by 6.5% in the fourth quarter. Northern Trust Corp now owns 318,287 shares of the biotechnology company’s stock valued at $34,734,000 after buying an additional 19,473 shares during the period. Meeder Asset Management Inc. boosted its holdings in Sarepta Therapeutics by 1,621.5% during the fourth quarter. Meeder Asset Management Inc. now owns 2,565 shares of the biotechnology company’s stock worth $281,000 after purchasing an additional 2,416 shares during the last quarter. Columbus Circle Investors boosted its holdings in Sarepta Therapeutics by 57.7% during the first quarter. Columbus Circle Investors now owns 392,243 shares of the biotechnology company’s stock worth $46,751,000 after purchasing an additional 143,552 shares during the last quarter. Daiwa Securities Group Inc. boosted its holdings in Sarepta Therapeutics by 1,939.8% during the fourth quarter. Daiwa Securities Group Inc. now owns 7,282 shares of the biotechnology company’s stock worth $795,000 after purchasing an additional 6,925 shares during the last quarter. Finally, Piedmont Investment Advisors Inc. boosted its holdings in Sarepta Therapeutics by 6.2% during the fourth quarter. Piedmont Investment Advisors Inc. now owns 4,821 shares of the biotechnology company’s stock worth $526,000 after purchasing an additional 280 shares during the last quarter. Institutional investors own 93.48% of the company’s stock.

NASDAQ SRPT opened at $115.85 on Wednesday. The company has a debt-to-equity ratio of 0.41, a quick ratio of 7.49 and a current ratio of 8.21. Sarepta Therapeutics Inc has a 1 year low of $86.55 and a 1 year high of $176.50. The firm has a market cap of $8.62 billion, a price-to-earnings ratio of -21.22 and a beta of 1.98.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings results on Wednesday, May 8th. The biotechnology company reported ($1.07) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($2.05) by $0.98. Sarepta Therapeutics had a negative net margin of 124.66% and a negative return on equity of 42.67%. The firm had revenue of $87.01 million for the quarter, compared to analyst estimates of $86.92 million. Equities research analysts anticipate that Sarepta Therapeutics Inc will post -4.71 EPS for the current year.

Several research analysts recently commented on SRPT shares. Royal Bank of Canada restated an “outperform” rating and set a $164.00 target price on shares of Sarepta Therapeutics in a report on Thursday, January 17th. Zacks Investment Research upgraded shares of Sarepta Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, January 23rd. Piper Jaffray Companies increased their target price on shares of Sarepta Therapeutics from $168.00 to $200.00 and gave the stock an “overweight” rating in a report on Wednesday, January 30th. BidaskClub upgraded shares of Sarepta Therapeutics from a “hold” rating to a “buy” rating in a report on Monday, February 4th. Finally, BTIG Research set a $190.00 target price on shares of Sarepta Therapeutics and gave the stock a “buy” rating in a report on Tuesday, February 5th. One research analyst has rated the stock with a hold rating, twenty-seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $193.00.

ILLEGAL ACTIVITY WARNING: “Los Angeles Capital Management & Equity Research Inc. Purchases Shares of 2,180 Sarepta Therapeutics Inc (SRPT)” was posted by The Lincolnian Online and is the property of of The Lincolnian Online. If you are reading this story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this story can be viewed at https://www.thelincolnianonline.com/2019/05/15/los-angeles-capital-management-equity-research-inc-purchases-shares-of-2180-sarepta-therapeutics-inc-srpt.html.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare diseases. The company offers EXONDYS 51, a disease-modifying therapy for duchenne muscular dystrophy (DMD). Its products pipeline include Golodirsen, a product candidate that binds to exon 53 of dystrophin pre-mRNA, which results in exclusion or skipping of exon during mRNA processing in patients with genetic mutations; and Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene.

Read More: Fiduciary

Want to see what other hedge funds are holding SRPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sarepta Therapeutics Inc (NASDAQ:SRPT).

Institutional Ownership by Quarter for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.